A novel approach to synaptic protection and restoration in Alzheimer’s disease

New Targets

Until very recently, the understanding and availability of drug targets in Alzheimer’s has been sparse and concentrated on acetylcholinesterase, NMDA receptors or insoluble amyloid plaque. Cognition Therapeutics has taken a new approach, using the new concept that soluble Aβ oligomers are the primary neurotoxic element causing neuronal degeneration and cognitive decline in Alzheimer’s disease and discovered a brand new drug target, the sigma-2/PGRMC1 receptor.

New Drugs

The therapeutic standards of care for Alzheimer’s only treat the cognitive symptoms, do not modify disease progression and at best they are only modestly active, gradually losing their efficacy as the disease becomes more severe. Cognition Therapeutics has applied its innovative drug discovery platform and discovered first in-class small molecule inhibitors of Aβ oligomer binding to neurons that have the potential to modify disease progression in Alzheimer’s disease.

New Hope

Recent clinical advances using Aβ monoclonal antibodies that interact with both soluble Aβ oligomers and insoluble fibrillar Aβ, have demonstrated a reduction in Aβ burden correlating with a slowing of cognitive decline in early Alzheimer’s patients and have renewed confidence in the Aβ approach. Cognition Therapeutics has a first candidate in the clinic and has back-up candidates moving through its late preclinical pipeline.

Cognition Therapeutics’ leadership team has deep experience in the development and marketing of novel therapeutics.
Cognition’s proprietary biological discovery platform, through which Elayta was identified, is based on unbiased phenotypic screens in the target cell population of mature primary neurons.